Eli Lilly and Company
@EliLillyandCo
Uniting caring with discovery to create medicines that make life better worldwide. Lilly’s official account (formerly LillyPad)
Joined July 2010
1.2K Following 145.5K Followers
In addition to weight loss, our investigational triple agonist reduced moderate-to-severe obstructive sleep apnea severity by an average 61 percent on the 9 mg dose in the TRIUMPH-1 study. Presented today at #ADA2026#. Read more:
Show more
